Pelthos Therapeutics Inc. Proceeds from Related Party Debt
Pelthos Therapeutics Inc. (PTHS) reported Proceeds from Related Party Debt of $131.87 thousand for the 6-month period ending 2024-06-30, per its 10-Q filed 2025-08-13.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromRelatedPartyDebt · last filed 2025-08-13
- Pelthos Therapeutics Inc. proceeds from related party debt for the quarter ending 2023-12-31 was $155.00K.
- Pelthos Therapeutics Inc. proceeds from related party debt for the quarter ending 2023-09-30 was $107.28K.
- Pelthos Therapeutics Inc. proceeds from related party debt for the quarter ending 2023-06-30 was $136.75K.
- Pelthos Therapeutics Inc. proceeds from related party debt for the quarter ending 2023-03-31 was $166.90K.
- Pelthos Therapeutics Inc. proceeds from related party debt for fiscal 2023 was $565.93K, a 465.93% increase from fiscal 2022.
- Pelthos Therapeutics Inc. proceeds from related party debt for fiscal 2022 was $100.00K.
| Period end | Proceeds from Related Party Debt 3 month | Proceeds from Related Party Debt 6 month | Proceeds from Related Party Debt 9 month | Proceeds from Related Party Debt 12 month |
|---|---|---|---|---|
| 2024-06-30 | $131.87K 10-Q · filed 2025-08-13 | |||
| 2023-12-31 | $155.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $262.28K derived: sum of 2 quarters · filed 2025-03-27 | $399.02K derived: sum of 3 quarters · filed 2025-03-27 | $565.93K 10-K · filed 2025-03-27 |
| 2023-09-30 | $107.28K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $244.03K derived: sum of 2 quarters · filed 2024-11-13 | $410.93K 10-Q · filed 2024-11-13 | |
| 2023-06-30 | $136.75K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $303.65K 10-Q · filed 2024-08-13 | ||
| 2023-03-31 | $166.90K 10-Q · filed 2024-05-15 | |||
| 2022-12-31 | $100.00K 10-K · filed 2024-04-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |